Tilray Brands has acquired the Lyphe Group, a UK-based medical cannabis clinic and digital pharmacy platform.
In an announcement on April 15, 2026, the company said the move will help to anchor and expand Tilray Medical’s footprint in the medical cannabis market in the United Kingdom.
Lyphe Group has dispensed approximately 150,000 units to date, and Lyphe Clinic has treated over 16,000 patients to date. The acquisition means Tilray Medical is establishing its first fully vertically integrated, patient-centric medical platform. This combines pharmaceutical-grade medical cannabis cultivation and production with clinical care, dispensing services, and pharmaceutical distribution.
Tilray says the integration of Lyphe’s highly skilled patient care team further differentiates this model, enabling a more personalized, seamless, and comprehensive approach to patient care and outcomes. Tilray will also leverage CC Pharma’s established scale, sourcing capabilities, and purchasing power to more efficiently supply medications through the Lyphe platform, supporting broader patient needs across the UK and further strengthening Tilray’s European pharmaceutical distribution network.
“I’m proud to welcome the Lyphe team to Tilray, bringing deep clinical expertise and a strong patient-first approach that immediately strengthens our capabilities,” said Rajnish Ohri, President, International, Tilray Brands. “This acquisition marks an important step in the continued expansion of Tilray Medical as a global healthcare platform.
“By integrating Lyphe Group’s clinical and dispensing expertise and digital patient access with our established pharmaceutical distribution capabilities, we are enhancing our ability to serve patients across the UK. We expect this business to be accretive in 2027 and see a compelling opportunity to build a fully connected, international medical ecosystem that delivers consistent, high-quality care while expanding access to both medical cannabis and traditional therapies.”
In the same press release, Tilray says it continues to be positioned for US cannabis rescheduling and any potential medical cannabis opportunities. This includes evaluating its participation in the US Center for Medicare and Medicaid Innovation pilot program, which provides the opportunity to partner with Accountable Care Organizations and oncology practices to supply underserved and vulnerable patients with hemp-derived medical cannabis to provide therapeutic, safe access to medical cannabinoid products and gather data on patient outcomes.
“Upon rescheduling, Tilray Medical is strategically positioned to participate in a US regulated medical cannabis market, evidenced by our proven track record of operating at scale in highly-regulated medical cannabis markets globally, supported by our pharmaceutical quality systems, scientific expertise, and our ongoing commitment to education and clinical research,” said Denise Faltischek, Chief Strategy Officer and Head of M&A, Tilray Brands. “We believe that rescheduling will occur in the near-term and, when it does, we are well-positioned to seize the opportunity.”
The acquisition is not the company’s first foray into the UK medical cannabis market. In February, Tilray Pharma announced it had entered into a strategic agreement with a UK-based pharmaceutical distribution partner to expand its product availability across the United Kingdom.
Since 2018, doctors in the UK have been able to prescribe medical cannabis for medicinal use for patients with medical conditions that have failed to respond to first-line medications.
The strategic agreement will leverage the UK-based pharmaceutical distributor Smartway Pharmaceuticals’ established national distribution infrastructure to facilitate the delivery of pharmaceutical products and CC Pharma’s European procurement capability and GMP capacity.
Tilray estimates that the UK pharmaceutical market is worth nearly £1 billion (C$1.85 billion) within this category and believes this agreement positions it and CC Pharma to work with Smartway to accelerate access, improve supply reliability, and expand reach through trusted healthcare channels.
Tilray Brands Inc. reported net revenue of US$206.7 million for the three months ended February 28, 2026 (Q3 FY2026), gross profit of US$55 million and a net loss of US$25.2 million. The company’s revenue from international cannabis sales in the most recent quarter was US$24.1 million, about one-third of total net cannabis revenue.
Tilray Brands acquires Lyphe Group, expanding UK medical cannabis footprint
